CN109071405A - 使用治疗有效量的二羧酸化合物预防、治疗和逆转疾病 - Google Patents

使用治疗有效量的二羧酸化合物预防、治疗和逆转疾病 Download PDF

Info

Publication number
CN109071405A
CN109071405A CN201780024057.7A CN201780024057A CN109071405A CN 109071405 A CN109071405 A CN 109071405A CN 201780024057 A CN201780024057 A CN 201780024057A CN 109071405 A CN109071405 A CN 109071405A
Authority
CN
China
Prior art keywords
compound
electron
disease
dicarboxylic acid
withdrawing group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780024057.7A
Other languages
English (en)
Chinese (zh)
Inventor
布鲁斯·A·弗里曼
弗朗西斯科·J·朔普费尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of CN109071405A publication Critical patent/CN109071405A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201780024057.7A 2016-03-04 2017-03-02 使用治疗有效量的二羧酸化合物预防、治疗和逆转疾病 Pending CN109071405A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662303960P 2016-03-04 2016-03-04
US62/303,960 2016-03-04
PCT/US2017/020477 WO2017151938A1 (en) 2016-03-04 2017-03-02 Prevention, treatment and reversal of disease using therapeutically effective amounts of dicarboxylic acid compounds

Publications (1)

Publication Number Publication Date
CN109071405A true CN109071405A (zh) 2018-12-21

Family

ID=59743189

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780024057.7A Pending CN109071405A (zh) 2016-03-04 2017-03-02 使用治疗有效量的二羧酸化合物预防、治疗和逆转疾病

Country Status (6)

Country Link
US (2) US10751310B2 (https=)
EP (1) EP3440045B1 (https=)
JP (1) JP6959246B2 (https=)
CN (1) CN109071405A (https=)
CA (1) CA3016180A1 (https=)
WO (1) WO2017151938A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10765652B2 (en) 2016-10-05 2020-09-08 University of Pittsburgh—of the Commonwealth System of Higher Education Reversible nitroxide derivatives of nitroalkenes that mediate nitrosating and alkylating reactions
JP2019529501A (ja) 2016-10-05 2019-10-17 ユニバーシティ オブ ピッツバーグ−オブ ザ コモンウェルス システム オブ ハイヤー エデュケーションＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｐｉｔｔｓｂｕｒｇｈ Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ 可逆的に保護された、チオレート化求電子性脂肪酸としてのプロドラッグ
CN109200043A (zh) * 2018-10-23 2019-01-15 华南农业大学 二羧酸（盐）在降低脂肪沉积和预防肥胖方面的应用
CN112996493A (zh) * 2018-11-14 2021-06-18 高等教育联邦系统-匹兹堡大学 作为rad51抑制剂的亲电试剂和亲电前药
CA3209453A1 (en) * 2021-01-25 2022-07-28 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives therof, and their use for the prevention or treatment of disease

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1153464A (en) * 1965-08-25 1969-05-29 Lepetit Spa Amino-Fluoro-Aliphatic Dicarboxylic Acids and a process for their preparation
US3527789A (en) * 1967-10-06 1970-09-08 Shell Oil Co Production of poly(lower)alkyl alkenepolycarboxylates
WO2002022627A2 (en) * 2000-09-15 2002-03-21 Georgetwon University Ligands for metabotropic glutamate receptors
DE102011118462A1 (de) * 2011-11-14 2013-05-16 Maximilian Born Energetische Polymere als reaktive Strukturmaterialien zur Verwendung für Waffensysteme
WO2013142206A1 (en) * 2012-03-21 2013-09-26 P2 Science, Inc. Guerbet alcohols and methods for preparing and using same
WO2013162924A1 (en) * 2012-04-24 2013-10-31 Stepan Company Synergistic surfactant blends
WO2015012367A1 (ja) * 2013-07-26 2015-01-29 宇部興産株式会社 トリカルボン酸、トリカルボン酸エステル、およびそれらを含有する電解コンデンサ用電解液

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166913A (en) * 1977-07-08 1979-09-04 Atlantic Richfield Company Preparation of unsaturated diesters by the catalytic oxidative carbonylation of diolefins with an enol ether and an alcohol
EP0344113A3 (de) 1988-05-27 1990-10-31 Ciba-Geigy Ag Substituierte alpha-Pyrone und Naphthochinone
EP2679224A1 (en) 2007-08-01 2014-01-01 University of Pittsburgh of the Commonwealth System of Higher Education Nitro oleic acid modulation of type II diabetes
EP2100604B1 (en) * 2008-03-10 2012-07-04 Nestec S.A. Medium chain dicarboxylic acids and their derivates and metabolic disorders
WO2010005521A1 (en) 2008-06-30 2010-01-14 Bltn, Llc Azelaic acid ester compositions and methods for diagnosing and treating tissue conditions using azelaic acid ester compositions and proteinaceous biomarkers
WO2010014889A2 (en) 2008-08-01 2010-02-04 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Nitro fatty acids as regiomers and related mimetics
EP2459189A4 (en) 2009-07-31 2013-01-16 Univ Pittsburgh FATTY ACIDS AS ANTI-INFLAMMATORY AGENTS
EP2809317A4 (en) 2012-02-03 2015-07-22 Univ Pittsburgh FATTY ACIDS AS ANTI-INFLAMMATORY ACTIVE SUBSTANCES
TWI515296B (zh) * 2013-10-11 2016-01-01 中央研究院 反式－烏頭酸化合物於抑制第七型磷酸二酯酶的用途及於製備藥品與保健食品的用途
CN103705499B (zh) * 2013-12-13 2015-11-18 南京医科大学 二羧酸及其酯类化合物的应用
US20150216825A1 (en) * 2014-02-06 2015-08-06 University Of Houston System Organic acids as growth inhibitors of pathological calcification and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1153464A (en) * 1965-08-25 1969-05-29 Lepetit Spa Amino-Fluoro-Aliphatic Dicarboxylic Acids and a process for their preparation
US3527789A (en) * 1967-10-06 1970-09-08 Shell Oil Co Production of poly(lower)alkyl alkenepolycarboxylates
WO2002022627A2 (en) * 2000-09-15 2002-03-21 Georgetwon University Ligands for metabotropic glutamate receptors
DE102011118462A1 (de) * 2011-11-14 2013-05-16 Maximilian Born Energetische Polymere als reaktive Strukturmaterialien zur Verwendung für Waffensysteme
WO2013142206A1 (en) * 2012-03-21 2013-09-26 P2 Science, Inc. Guerbet alcohols and methods for preparing and using same
WO2013162924A1 (en) * 2012-04-24 2013-10-31 Stepan Company Synergistic surfactant blends
WO2015012367A1 (ja) * 2013-07-26 2015-01-29 宇部興産株式会社 トリカルボン酸、トリカルボン酸エステル、およびそれらを含有する電解コンデンサ用電解液

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ANNE-CE´LINE CANTET ET.AL: ""A new synthesis of trifluorinated compounds via 1,1-dichloro-1-alkenes in superacid""", 《TETRAHEDRON LETTERS》 *
B. W. BAKE ET.AL: ""Anodic Syntheses. Pnrt X I V.* The Use of Acetylenic Components.A New Synthesis of Oleic Acid"", 《AFTODIC SYFITHESES》 *
BIRGITTA ELIASSON ET.AL: ""Aliphatic medium chain tricarboxylic acids in rat urine"", 《JOURNAL OF LIPID RESEORCH》 *
DA-ZHEN XU ET.AL: ""A simple and highly efficient procedure for construction of quaternary carbons centers by tributylphosphine catalyzed bis-Michael addition"", 《TETRAHEDRON》 *
FRANZ EFFENBERGER ET.AL: ""Selective Hydrolysis of Aliphatic Dinitriles to Monocarboxylic Acids by a Nitrilase from Arabidopsis thaliana"", 《SYNTHESIS》 *
K. R. TSAI ET.AL: ""A Novel Synthesis of 1,21-Heneicosanedioic Acid""", 《J. ORG. CHEM》 *
SERGI HERVE AKONE ET.AL: ""2-Pentenedioic acid derivatives from a soil-derived fungus Gongronella butleri"", 《PHYTOCHEMISTRY LETTERS》 *
STN: "RN号为110107-16-9", 《STN REGISTRY》 *
STN: "RN号为127351-44-4", 《STN REGISTRY》 *
STN: "RN号为133827-59-5", 《STN REGISTRY》 *
STN: "RN号为63408-00-4", 《STN REGISTRY》 *
VON ALOIS ZIIRCHER ET.AL: ""179. Die Oxidation von 3-( 1-Nitro-2-oxocycloalkyl)propanal"", 《HELVETICA CHIMICA ACT》 *
YUNG-SON HON, ET.AL: ""Syntheses of Bifunctional Compounds from Cycloalkenes via Ozonide Intermediates"", 《TETRAHEDRON》 *

Also Published As

Publication number Publication date
EP3440045A4 (en) 2020-04-15
US20200360323A1 (en) 2020-11-19
EP3440045A1 (en) 2019-02-13
JP6959246B2 (ja) 2021-11-02
US10751310B2 (en) 2020-08-25
US20190091186A1 (en) 2019-03-28
JP2019512475A (ja) 2019-05-16
CA3016180A1 (en) 2017-09-08
WO2017151938A1 (en) 2017-09-08
US11642325B2 (en) 2023-05-09
EP3440045B1 (en) 2025-08-20

Similar Documents

Publication Publication Date Title
AU2014340182B2 (en) Cromolyn derivatives and related methods of imaging and treatment
US11801316B2 (en) Cromolyn derivatives and related methods of imaging and treatment
CN109071405A (zh) 使用治疗有效量的二羧酸化合物预防、治疗和逆转疾病
JP2023030072A (ja) 併用療法
CN102341391B (zh) 色甘酸衍生物以及制备成像和治疗的药物中的应用
US5084481A (en) Method of treating inflammatory diseases with pharmaceutical composition containing dihydrolipoic acid as active substance
JPS62249923A (ja) パ−キンソン病、うつ病、ナルコレプシ−および脳器官精神症候群の抑制用薬剤およびその製造方法
JP7368354B2 (ja) 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
EP3525780B1 (en) Pluripotent anti-inflammatory and metabolic modulators for the treatment of inflammation related conditions
AU2007341218A1 (en) Isosorbide mononitrate derivatives for the treatment of intestinal disorders
CN109803648A (zh) 可逆保护的硫醇化亲电脂肪酸作为前药
CN102225896B (zh) 大黄酸的醚衍生物以及它们的治疗用途
JP7498504B2 (ja) 脳神経または心臓保護剤としてのアミノチオール系化合物の使用
US20200222366A1 (en) Compound for treating osteoarthritis
EP4685128A1 (en) Novel 2-(1-hydroxypentyl) benzoic acid cycloalkyl amine salt
CN102964250A (zh) 氟比洛芬丁香酚酯药用化合物及其制剂和制备方法
JPS6144819A (ja) プロスタグランジンｉ２類縁化合物を含有する循環改善作用を有する薬剤
JPH0825883B2 (ja) 腎炎治療剤
JP7498475B2 (ja) 多発性骨髄腫の治療剤
HK40004503A (en) Prevention, treatment and reversal of disease using therapeutically effective amounts of dicarboxylic acid compounds
HK40004503B (en) Prevention, treatment and reversal of disease using therapeutically effective amounts of dicarboxylic acid compounds
JPH02262519A (ja) 糖尿病性神経障害治療剤
EP3732162B1 (en) Nitroalkene non steroidal anti-inflammatory drugs (na-nsaids) and methods of treating inflammation related conditions
Fukami et al. PS-BPB03-5: DEVELOPMENT OF A THERAPEUTIC VACCINE FOR DYSLIPIDEMIA AND RELATED DISEASES TARGETING ANGIOPOIETIN-LIKE PROTEIN 3 (ANGPTL3).
JPH0653678B2 (ja) アレルギ−性疾患治療剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20181221

RJ01 Rejection of invention patent application after publication